Praxis Capital acquires management rights of health supplement firm SeungMyeong PE firm purchases shares worth $49 mil
Translated by Kim So-in 공개 2021-09-17 12:57:40
이 기사는 2021년 09월 17일 08:08 thebell 에 표출된 기사입니다.
Seoul-based private equity (PE) firm Praxis Capital has acquired South Korean health supplement company SeungMyeong to capitalize on the fast-growing health supplement market and the company’s competitiveness in the global market.Praxis Capital signed a contract with the company to purchase shares worth 58 billion won ($49 million) to secure management rights in July, industry sources said on Wednesday. The acquisition was fully financed through the PE firm’s blind-pool fund.
Established in 2008, SeungMyeong operates health supplement brands like Naturalize and The REAL, whose main product categories include omega 3, propolis, and gamma-linolenic acid.
The company has built overseas networks in North America, Oceania, and Europe over the past 10 years to focus on the product development. It also owns more than 400 stock keeping units and is developing private brands for more than 30 retailers.
Praxis Capital has primarily reviewed the company’s competitiveness in the health supplement market to make the latest investment. The health supplement market was estimated to be worth around 6 trillion won in 2020 and is expected to grow fast in the coming years as consumption trends change. SeungMyeong posted revenue of around 30 billion won in 2020, with an average annual revenue growth of 50% over the last three years.
Praxis Capital plans to further enhance the company’s products beyond the health supplement category through the latest buyout investment as the company’s mainstay products have already secured top positions on the country's major ecommerce platforms such as Naver and Coupang. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [한경협 파이낸셜 리포트]'돈 굴리기' 보수적 접근, '채권 투자' 집중
- 콤텍시스템, 'BM 금융 솔루션 데이' 개최
- OTT 티빙, 마케팅담당 임원 '컬리→배민 출신'으로
- [보험경영분석]ABL생명, 투자부문 금리효과에 흑자…진짜는 '회계효과'
- [여전사경영분석]JB우리캐피탈, 고수익 자산 중심 포트폴리오 개편 지속
- [보험사 IFRS17 조기도입 명암]에이스손보, 지급여력비율 개선의 이면 '계약감소'
- [보험 패러다임 시프트]IFRS17에 바뀐 경영전략…'퍼스트 무버' 총력전
- [보험사 해외사업 점검]삼성생명, 성장 느린 태국법인…자산운용 투자 '속도'
- [2금융권 연체 리스크]현대카드, 최상위 건전성 지표…현금서비스·리볼빙 주의
- [보험사 IFRS17 조기도입 명암]DB손보, 새 제도 도입 후 계약부채 확 줄었다